Inhibition of prohormone convertases PC1/3 and PC2 by 2,5- dideoxystreptamine derivatives

Molecular Pharmacology

Volumn 81, Issue 3, 2012, Pages 440-454

  Vivoli, Mirella ^a   Caulfield, Thomas R ^b   Martínez Mayorga, Karina ^b   Johnson, Alan T ^c   Jiao, Guan Sheng ^c   Lindberg, Iris ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c PanThera Biopharma LL ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIDEOXYSTREPTAMINE DERIVATIVE; ENZYME INHIBITOR; GLUCAGON; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 2; PROPROTEIN CONVERTASE 3; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; MOUSE; NONHUMAN; PANCREAS CELL; PRIORITY JOURNAL;

ANIMALS; CELL LINE; ENZYME INHIBITORS; HEXOSAMINES; INHIBITORY CONCENTRATION 50; KINETICS; MICE; PROPROTEIN CONVERTASES;

EID: 84857395820     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.077040     Document Type: Article

References (60)

1. Angliker H, Wikstrom P, Shaw E, Brenner C, and Fuller RS (1993) The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast. Biochem J 293:75-81. (Pubitemid 23223148)
2. Apletalina E, Appel J, Lamango NS, Houghten RA, and Lindberg I (1998) Identification of inhibitors of prohormone convertases 1 and 2 using a peptide combinatorial library. J Biol Chem 273:26589-26595. (Pubitemid 28471670)
3. Apletalina EV, Juliano MA, Juliano L, and Lindberg I (2000a) Structure-function analysis of the 7B2 CT peptide. Biochem Biophys Res Commun 267:940-942. (Pubitemid 30099427)
4. Apletalina EV, Muller L, and Lindberg I (2000b) Mutations in the catalytic domain of prohormone convertase 2 result in decreased binding to 7B2 and loss of inhibition with 7B2 C-terminal peptide. J Biol Chem 275:14667-14677. (Pubitemid 30339758)
5. Arnaoutova I, Smith AM, Coates LC, Sharpe JC, Dhanvantari S, Snell CR, Birch NP, and Loh YP (2003) The prohormone processing enzyme PC3 is a lipid raftassociated transmembrane protein. Biochemistry 42:10445-10455. (Pubitemid 37071444)
6. Basak A, Cooper S, Roberge AG, Banik UK, Chrétien M, and Seidah NG (1999) Inhibition of proprotein convertases-1, -7 and furin by diterpines of Andrographis paniculata and their succinoyl esters. Biochem J 338:107-113. (Pubitemid 29097292)
7. Basak A and Lotfipour F (2005) Modulating furin activity with designed mini-PDX peptides: synthesis and in vitro kinetic evaluation. FEBS Lett 579:4813-4821. (Pubitemid 41218669)
8. Becker GL, Sielaff F, Than ME, Lindberg I, Routhier S, Day R, Lu Y, Garten W, and Steinmetzer T (2010) Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem 53:1067-1075.
9. Benjannet S, Mamarbachi AM, Hamelin J, Savaria D, Munzer JS, Chrétien M, and Seidah NG (1998) Residues unique to the prohormone convertase PC2 modulate its autoactivation, binding to 7B2 and enzymatic activity. FEBS Lett 428:37-42. (Pubitemid 28266823)
10. Bogdanovic S and Langlands B (2005) Proteases: Technologies and Opportunities for Drug Discovery, D&MD Publications, Westborough, MA.
11. Bonic A and Mackin RB (2003) Expression, purification, and PC1-mediated processing of human proglucagon, glicentin, and major proglucagon fragment. Protein Expr Purif 28:15-24.
12. Boudreault A, Gauthier D, and Lazure C (1998a) Proprotein convertase PC1/3- related peptides are potent slow tight- binding inhibitors of murine PC1/3 and Hfurin. J Biol Chem 273:31574-31580. (Pubitemid 28533181)
13. Boudreault A, Gauthier D, Rondeau N, Savaria D, Seidah NG, Chrétien M, and Lazure C (1998b) Molecular characterization, enzymatic analysis, and purification of murine proprotein convertase-1/3 (PC1/PC3) secreted from recombinant baculovirus- infected insect cells. Protein Expr Purif 14:353-366. (Pubitemid 29020369)
14. Brinkerhoff CJ, Podsiadlo P, Komiyama T, Fuller RS, and Blum O (2002) Protease inhibitors formed in situ from copper and tridentate chelates: a generalized approach towards metal-based pharmaceuticals. Chembiochem 3:1141-1143. (Pubitemid 36008047)
15. Brylinski M and Skolnick J (2008) A threading-based method (FINDSITE) for ligand-binding site prediction and functional annotation. Proc Natl Acad Sci USA 105:129-134.
16. Cameron A, Apletalina EV, and Lindberg I (2001) The enzymology of PC1 and PC2, in The Enzymes (Dalbey RE ed) pp 291-331, Academic Press, San Diego.
17. Cameron A, Appel J, Houghten RA, and Lindberg I (2000a) Polyarginines are potent furin inhibitors. J Biol Chem 275:36741-36749. (Pubitemid 32002081)
18. Cameron A, Fortenberry Y, and Lindberg I (2000b) The SAAS granin exhibits structural and functional homology to 7B2 and contains a highly potent hexapeptide inhibitor of PC1. FEBS Lett 473:135-138. (Pubitemid 30254276)
19. Copeland RA (2005) Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, Wiley & Sons-Interscience Hoboken, New Jersey.
20. Cornwall GA, Cameron A, Lindberg I, Hardy DM, Cormier N, and Hsia N (2003) The cystatin-related epididymal spermatogenic protein inhibits the serine protease prohormone convertase 2. Endocrinology 144:901-908. (Pubitemid 36262856)
21. Dahlen JR, Jean F, Thomas G, Foster DC, and Kisiel W (1998) Inhibition of soluble recombinant furin by human proteinase inhibitor 8. J Biol Chem 273:1851-1854. (Pubitemid 28069224)
22. Day R, Schafer MK, Watson SJ, Chrétien M, and Seidah NG (1992) Distribution and regulation of the prohormone convertases PC1 and PC2 in the rat pituitary. Mol Endocrinol 6:485-497.
23. Decroly E, Vandenbranden M, Ruysschaert JM, Cogniaux J, Jacob GS, Howard SC, Marshall G, Kompelli A, Basak A, and Jean F (1994) e The convertases furin and PC1 can both cleave the human immunodeficiency virus (HIV)-1 envelope glycoprotein gp160 into gp120 (HIV-1 SU) and gp41 (HIV-I TM). J Biol Chem 269: 12240-12247.
24. Dufour EK, Denault JB, Bissonnette L, Hopkins PC, Lavigne P, and Leduc R (2001) The contribution of arginine residues within the P6-P1 region of alpha 1-antitrypsin to its reaction with furin. J Biol Chem 276:38971-38979.
25. Farooqi IS, Volders K, Stanhope R, Heuschkel R, White A, Lank E, Keogh J, O'Rahilly S, and Creemers JW (2007) Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3. J Clin Endocrinol Metab 92:3369-3373. (Pubitemid 47435306)
26. Fugère M and Day R (2005) Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci 26:294-301. (Pubitemid 40733522)
27. Fugère M, Limperis PC, Beaulieu-Audy V, Gagnon F, Lavigne P, Klarskov K, Leduc R, and Day R (2002) Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains. J Biol Chem 277:7648-7656. (Pubitemid 34968209)
28. Furuta M, Yano H, Zhou A, Rouillé Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, and Steiner DF (1997) Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA 94:6646-6651. (Pubitemid 27281918)
29. Heni M, Haupt A, Schâfer SA, Ketterer C, Thamer C, Machicao F, Stefan N, Staiger H, Häring HU, and Fritsche A (2010) Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion. BMC Med Genet 11:86.
30. Henrich S, Cameron A, Bourenkov GP, Kiefersauer R, Huber R, Lindberg I, Bode W, and Than ME (2003) The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 10:520-526. (Pubitemid 36792902)
31. Henrich S, Lindberg I, Bode W, and Than ME (2005) Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J Mol Biol 345:211-227. (Pubitemid 39574845)
32. Hernández-Campos A, Velázquez-Martínez I, Castillo R, López-Vallejo F, Jia P, Yu Y, Giulianotti MA, and Medina-Franco JL (2010) Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold. Chem Biol Drug Des 76:269-276.
33. Hoshino A, Kowalska D, Jean F, Lazure C, and Lindberg I (2011) Modulation of PC1/3 activity by self-interaction and substrate binding. Endocrinology 152:1402-1411.
34. Humphrey W, Dalke A, and Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-38. (Pubitemid 26152973)
35. Jiao GS, Cregar L, Goldman ME, Millis SZ, and Tang C (2006a) Guanidinylated 2,5-dideoxystreptamine derivatives as anthrax lethal factor inhibitors. Bioorg Med Chem Lett 16:1527-1531. (Pubitemid 43197516)
36. Jiao GS, Cregar L, Wang J, Millis SZ, Tang C, O'Malley S, Johnson AT, Sareth S, Larson J, and Thomas G (2006b) Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc Natl Acad Sci USA 103:19707-19712. (Pubitemid 46037496)
37. Jutras I, Seidah NG, Reudelhuber TL, and Brechler V (1997) Two activation states of the prohormone convertase PC1 in the secretory pathway. J Biol Chem 272: 15184-15188. (Pubitemid 27255534)
38. Komiyama T, Coppola JM, Larsen MJ, van Dort ME, Ross BD, Day R, Rehemtulla A, and Fuller RS (2009) Inhibition of furin/proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem 284:15729-15738.
39. Komiyama T, VanderLugt B, Fugère M, Day R, Kaufman RJ, and Fuller RS (2003) Optimization of protease-inhibitor interactions by randomizing adventitious contacts. Proc Natl Acad Sci USA 100:8205-8210. (Pubitemid 36842523)
40. Kowalska D, Liu J, Appel JR, Ozawa A, Nefzi A, Mackin RB, Houghten RA, and Lindberg I (2009) Synthetic small-molecule prohormone convertase 2 inhibitors. Mol Pharmacol 75:617-625.
41. Lloyd DJ, Bohan S, and Gekakis N (2006) Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice. Hum Mol Genet 15:1884-1893. (Pubitemid 43821779)
42. Mains RE and Eipper BA (2000) Proopiomelanocortin synthesis and cell-specific processing, in Handbook of Physiology, Section 7: The Endocrine System, Volume IV: Coping with the Environment: Neural and Endocrine Mechanisms, pp 85-101, Oxford University Press, London.
43. Motulsky HJ and Christopoulos A (2004) Fitting Models to Biological Data using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting, Oxford University Press, New York.
44. Oliva AA Jr, Chan SJ, and Steiner DF (2000) Evolution of the prohormone convertases: identification of a homologue of PC6 in the protochordate amphioxus. Biochim Biophys Acta 1477:338-348. (Pubitemid 30119911)
45. Peinado JR, Li H, Johanning K, and Lindberg I (2003) Cleavage of recombinant proenkephalin and blockade mutants by prohormone convertases 1 and 2: an in vitro specificity study. J Neurochem 87:868-878. (Pubitemid 37444563)
46. Pfützner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lübben G, and Forst T (2004) Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 27:682-687. (Pubitemid 38280533)
47. Podsiadlo P, Komiyama T, Fuller RS, and Blum O (2004) Furin inhibition by compounds of copper and zinc. J Biol Chem 279:36219-36227. (Pubitemid 39128957)
48. Qian Y, Devi LA, Mzhavia N, Munzer S, Seidah NG, and Fricker LD (2000) The C-terminal region of proSAAS is a potent inhibitor of prohormone convertase 1. J Biol Chem 275:23596-23601. (Pubitemid 30624643)
49. Quesada I, Tudurí E, Ripoll C, and Nadal A (2008) Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 199:5-19.
50. Rabah N, Gauthier D, Dikeakos JD, Reudelhuber TL, and Lazure C (2007) The C-terminal region of the proprotein convertase 1/3 (PC1/3) exerts a bimodal regulation of the enzyme activity in vitro. FEBS J 274:3482-3491. (Pubitemid 47024981)
51. Rhodes CJ, Thorne BA, Lincoln B, Nielsen E, Hutton JC, and Thomas G (1993) Processing of proopiomelanocortin by insulin secretory granule proinsulin processing endopeptidases. J Biol Chem 268:4267-4275. (Pubitemid 23072967)
52. Richer MJ, Keays CA, Waterhouse J, Minhas J, Hashimoto C, and Jean F (2004) The Spn4 gene of Drosophila encodes a potent furin-directed secretory pathway serpin. Proc Natl Acad Sci USA 101:10560-10565. (Pubitemid 38955781)
53. Rouillé Y, Bianchi M, Irminger JC, and Halban PA (1997) Role of prohormone convertase PC2 in the processing of proglucagon to glucagon. FEBS Lett 413:119-123. (Pubitemid 27348648)
54. Rufaut NW, Brennan SO, Hakes DJ, Dixon JE, and Birch NP (1993) Purification and characterization of the candidate prohormone-processing enzyme SPC3 produced in a mouse L cell line. J Biol Chem 268:20291-20298. (Pubitemid 23278935)
55. Smeekens SP, Montag AG, Thomas G, Albiges-Rizo C, Carroll R, Benig M, Phillips LA, Martin S, Ohagi S, and Gardner P (1992) Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. Proc Natl Acad Sci USA 89:8822-8826.
56. Spruce MC, Potter J, and Coppini DV (2003) The pathogenesis and management of painful diabetic neuropathy: a review. Diabet Med 20:88-98. (Pubitemid 36269649)
57. Villemure M, Fournier A, Gauthier D, Rabah N, Wilkes BC, and Lazure C (2003) Barley serine proteinase inhibitor 2-derived cyclic peptides as potent and selective inhibitors of convertases PC1/3 and furin. Biochemistry 42:9659-9668. (Pubitemid 36993138)
58. Zhou A, Bloomquist BT, and Mains RE (1993) The prohormone convertases PC1 and PC2 mediate distinct endoproteolytic cleavages in a strict temporal order during proopiomelanocortin biosynthetic processing. J Biol Chem 268:1763-1769. (Pubitemid 23033570)
59. Zhou Y and Lindberg I (1994) Enzymatic properties of carboxyl-terminally truncated prohormone convertase 1 (PC1/SPC3) and evidence for autocatalytic conversion. J Biol Chem 269:18408-18413. (Pubitemid 24224071)
60. Zhu X, Muller L, Mains RE, and Lindberg I (1998) Structural elements of PC2 required for interaction with its helper protein 7B2. J Biol Chem 273:1158-1164. (Pubitemid 28049217)